BILL ANALYSIS                                                                                                                                                                                                    



                                                                       


           ------------------------------------------------------------ 
          |SENATE RULES COMMITTEE            |                  SB 1307|
          |Office of Senate Floor Analyses   |                         |
          |1020 N Street, Suite 524          |                         |
          |(916) 445-6614         Fax: (916) |                         |
          |327-4478                          |                         |
           ------------------------------------------------------------ 
           
                                         
                                 THIRD READING


          Bill No:  SB 1307
          Author:   Figueroa (D)
          Amended:  4/14/04
          Vote:     21

           
           SENATE BUSINESS & PROFESSIONS COMMITTEE  :  4-1, 4/19/04
          AYES:  Cedillo, Machado, Murray, Figueroa
          NOES:  Aanestad
          NO VOTE RECORDED:  Brulte, Vincent

           SENATE APPROPRIATIONS COMMITTEE  :  Senate Rule 28.8


           SUBJECT  :    Wholesalers and manufacturers of dangerous  
          drugs and 
                      devices

           SOURCE  :     California Board of Pharmacy


           DIGEST  :    This bill revises the California Pharmacy Law  
          to, among other things, require all non-resident  
          prescription drug wholesalers to be licensed by the Board  
          of Pharmacy, require all prescription drugs to have a  
          pedigree by January 1, 2007 that will document the  
          transaction history of the distribution of those drugs, and  
          also revises restrictions on distribution of prescription  
          drugs, and imposes and increases penalties for violation of  
          these provisions of the law.

           ANALYSIS  :    

           Existing Law (the Pharmacy Law)
                                                           CONTINUED





                                                              SB 1307
                                                                Page  
          2


           1.Provides for the licensing and regulation of pharmacies,  
            and pharmacists and wholesalers of dangerous drugs or  
            devices (Rx drugs/devices) by the California State Board  
            of Pharmacy (Board) in the State Department of Consumer  
            Affairs.

          2.Requires that Rx drugs/devices be dispensed only by  
            licensed pharmacists and only to certain persons or  
            entities.  Provides certain exemptions for manufacturers,  
            veterinary food-animal drug retailers, and wholesalers,  
            including those that employ sufficient qualified  
            supervision by a person who possesses a certificate of  
            exemption (an "exemptee") from the Board.

          3.Requires the Board to take action against a licensee who  
            is guilty of "unprofessional conduct," as defined.

          4.Prohibits a person from acting as a wholesaler of Rx  
            drugs/devices without being licensed by the Board.

          5.Imposes certain licensing and registration requirements  
            on out-of-state manufacturers and wholesalers doing  
            business in California, and their principals.

          6.Requires any manufacturer who sells or transfers a Rx  
            drug/device into California, or who receives a Rx  
            drug/device from a person in California to, upon request,  
            furnish an authorized law enforcement officer with all  
            records or other documentation of that sale or transfer,  
            and makes a manufacturer who fails or refuses to comply  
            with that request subject to a citation and a fine, an  
            order of abatement, or both.

          This bill:

            1. Defines "closed door pharmacy."

            2. Requires the Board of Pharmacy to provide separate  
              designation for closed door pharmacies.

            3. Defines "designated representative" as a person  
              licensed pursuant to Section 4053.








                                                               SB 1307
                                                                Page  
          3

            4. Defines "designated representative-in-charge" as a  
              person licensed pursuant to Section 4053 who supervises  
              or manages a wholesaler.

            5. Defines "pedigree" to include a history of all  
              transactions of a particular dangerous drug from the  
              manufacturer to the pharmacy.

            6. Requires a pedigree to contain the following  
              information:

              A.     The name, license number and address of the  
                 source of the dangerous drug.

              B.     The quantity of the dangerous drug, its dosage  
                 form and strength, the date of the transaction, the  
                 sales invoice number, the container size, the number  
                 of containers, the expiration dates, and the lot  
                 numbers of the dangerous drug.

              C.     The business name, address, and if appropriate,  
                 the state license number of each owner of the  
                 dangerous drug, and the dangerous drug shipping  
                 information, including the name and address of each  
                 person certifying delivery or receipt of the  
                 dangerous drug.

              D.     A certification under penalty of perjury from a  
                 responsible party of the source of the dangerous  
                 drug that the information contained in the pedigree  
                 is true and accurate.

            7. Adds non-resident wholesaler to the definition of  
              "wholesaler."

            8. Changes "exemptee" to "designated representative"  
              throughout the Pharmacy Law.

            9. Modifies the existing requirement that an individual  
              seeking a license as designated representative must  
              have of one-year paid work experience to require that  
              the experience must have been in the prior three years.

           10. Clarifies the existing requirement that a designated  







                                                               SB 1307
                                                                Page  
          4

              representative must have knowledge of California law  
              relating to the distribution of dangerous drugs and  
              controlled substances.

           11. Exempts pharmaceutical manufacturers from the laws  
              governing the wholesale distribution of dangerous  
              drugs.

           12. Specifies that certificates of exemption issued prior  
              to January 1, 2005 are valid until the earlier of their  
              date of expiration or January 1, 2006.

           13. Specifies that existing holders of certificates of  
              exemption shall receive a license as a designated  
              representative upon satisfaction of the renewal  
              requirements for that license.

           14. Requires any pharmacy that meets the definition of a  
              closed door pharmacy to notify the board of that status  
              prior to the issuance or renewal of a pharmacy license.

           15. Restricts the furnishing of dangerous drugs by a  
              pharmacy to the following circumstances:

              A.     The wholesaler or manufacturer from whom the  
                 dangerous drug was acquired.

              B.     A licensed reverse distributor.

              C.     Another pharmacy or wholesaler to alleviate a  
                 temporary shortage of a dangerous drug that could  
                 result in the denial of health care. A pharmacy  
                 furnishing dangerous drugs pursuant to this  
                 paragraph may only furnish a quantity sufficient to  
                 alleviate the temporary shortage.

              D.     A patient pursuant to a prescription or as  
                 otherwise authorized by law.

              E.     A health care provider that is not a pharmacy  
                 but that is authorized to purchase dangerous drugs.

          16. Permits the Board of Pharmacy to issue citations and  
              fines for violations related to counterfeiting,  







                                                               SB 1307
                                                                Page  
          5

              specified wholesale violations or violations related to  
              a closed door pharmacy on a per occurrence basis and  
              permits the State Franchise Tax Board to collect those  
              fines referred by the Board of Pharmacy.

          17. Permits the Board of Pharmacy to issue a temporary  
              license to a wholesaler or to a non-resident  
              wholesaler.

          18. Requires all non-resident wholesalers to be licensed by  
              the Board of Pharmacy.

          19. Requires both wholesalers and non-resident wholesalers  
              to provide a surety bond of $100,000 to secure payment  
              of administrative fines and penalties imposed by the  
              Board of Pharmacy.

          20. Requires that dangerous drugs and dangerous devices be  
              purchased only from an appropriately licensed person.

          21. Requires the transmission of a pedigree from seller to  
              buyer of any dangerous drug after January 1, 2007.

          22. Permits the Board of Pharmacy to extend the effective  
              date of the pedigree requirement by up to one year if  
              additional time is needed to implement an electronic  
              pedigree system.

          23. Requires wholesalers to report excessive purchases of  
              dangerous drugs by a closed door pharmacy.

          24. Requires wholesalers to have a system to identify  
              significant changes in the purchasing patterns of a  
              closed door pharmacy.

          25. Requires wholesalers to provide the Board of Pharmacy  
              with purchase information related to a closed door  
              pharmacy upon request.

          26. Prohibits a local government from issuing a business  
              license to a wholesaler without a wholesaler license  
              issued by the Board of Pharmacy.

          27. Defines the excessive furnishing of dangerous drugs to  







                                                               SB 1307
                                                                Page  
          6

              a closed door pharmacy as unprofessional conduct.

          28. Makes numerous technical and clarifying changes to the  
              Pharmacy Law.

           Comments

           This bill is sponsored by the California Board of Pharmacy  
          to substantially decrease the threat of counterfeit drugs  
          and drug diversion.  Much of the bill draws from recently  
          adopted laws in Nevada and Florida and from recent draft  
          revisions to model laws published by the National  
          Association of Boards of Pharmacy.  The proposal is  
          designed to address challenges presented by the existing  
          distribution system for prescription drugs.

          NOTE:  See the Senate Business and Professions Committee  
                 analysis for background information.

           Recent Legislation

           AB 2682 (McLeod), in the Assembly Appropriations Committee,  
          will require all out-of-state wholesaler shipping Rx  
          drugs/devices into California to be licensed by the Board,  
          and requires the Board to adopt regulations governing the  
          wholesale distribution of Rx drugs and devices by anyone  
          who is not a manufacturer or the "authorized distributor"  
          of that Rx drug/device.   
           
           FISCAL EFFECT  :    Appropriation:  No   Fiscal Com.:  Yes    
          Local:  Yes

           SUPPORT  :   (Verified  4/30/04)

          California Board of Pharmacy (source)
          California Association of Health-System Pharmacists

           ARGUMENTS IN SUPPORT  :    According to the sponsor, the Food  
          and Drug Administration has seen a quadrupling of  
          counterfeit drug cases in recent years.  Recent articles  
          published in the Washington Post and the Los Angeles Times  
          also highlight the threat of drug counterfeiting and point  
          out that the drug distribution system has proven to be an  
          easy mark for savvy counterfeiters.  The Board states that  







                                                               SB 1307
                                                                Page  
          7

          the bill's provisions will substantially decrease the  
          threat of counterfeit drugs and drug diversion and  
          modernize our drug distribution system, thereby increasing  
          the safety and efficacy of prescription drugs taken by  
          patients.  The bill is designed to overcome some of the  
          weaknesses in the existing wholesale Rx drug/device  
          distribution system that enable counterfeit drugs to get  
          into it.  The bill will provide a means for being able to  
          ascertain the movements and transactions involving a  
          prescription drug from its manufacturer to pharmacy and the  
          ultimate consumer.  In addition to reducing the  
          introduction of counterfeit drugs, the bill will also  
          increase protection from situations where drugs are  
          improperly stored or shipped, leading to their  
          deterioration and danger to the patient who ultimately  
          takes the drug.


          CP:cm  5/4/04   Senate Floor Analyses 

                         SUPPORT/OPPOSITION:  SEE ABOVE

                                ****  END  ****